Phillip S. Pang

11.1k total citations · 2 hit papers
55 papers, 2.8k citations indexed

About

Phillip S. Pang is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Phillip S. Pang has authored 55 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hepatology, 30 papers in Epidemiology and 10 papers in Infectious Diseases. Recurrent topics in Phillip S. Pang's work include Hepatitis C virus research (40 papers), Liver Disease Diagnosis and Treatment (22 papers) and Hepatitis B Virus Studies (22 papers). Phillip S. Pang is often cited by papers focused on Hepatitis C virus research (40 papers), Liver Disease Diagnosis and Treatment (22 papers) and Hepatitis B Virus Studies (22 papers). Phillip S. Pang collaborates with scholars based in United States, France and New Zealand. Phillip S. Pang's co-authors include John G. McHutchison, Robert H. Hyland, Xiao Ding, William T. Symonds, Eric Lawitz, Evguenia S. Svarovskaia, Edward Gane, Hongmei Mo, Catherine Stedman and Fred Poordad and has published in prestigious journals such as Nature, The Lancet and Nucleic Acids Research.

In The Last Decade

Phillip S. Pang

55 papers receiving 2.7k citations

Hit Papers

Sofosbuvir and ledipasvir fixed-dose combination with and... 2013 2026 2017 2021 2013 2021 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    2013 438 citations Eric Lawitz, Phillip S. Pang et al. profile →
  2. After the pandemic: perspectives on the future trajectory of COVID-19
    2021 255 citations Amalio Telenti, Ann M. Arvin et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Phillip S. Pang United States 27 2.2k 2.0k 679 284 141 55 2.8k
F. Xavier López‐Labrador Spain 23 1.4k 0.6× 1.4k 0.7× 307 0.5× 146 0.5× 151 1.1× 72 2.0k
Nancy P. Lam United States 10 1.6k 0.7× 1.4k 0.7× 332 0.5× 133 0.5× 233 1.7× 14 2.2k
Khayriyyah Mohd Hanafiah Malaysia 8 1.8k 0.8× 1.6k 0.8× 323 0.5× 168 0.6× 82 0.6× 20 2.2k
Thelma E. Wiley United States 16 2.6k 1.2× 2.4k 1.2× 341 0.5× 135 0.5× 336 2.4× 31 3.2k
Enea Spada Italy 26 1.4k 0.6× 1.2k 0.6× 294 0.4× 117 0.4× 79 0.6× 62 1.8k
Mariantonietta Pisaturo Italy 26 1.3k 0.6× 1.4k 0.7× 257 0.4× 137 0.5× 72 0.5× 102 1.8k
Scott Bowden Australia 34 3.5k 1.6× 3.8k 1.9× 814 1.2× 238 0.8× 38 0.3× 89 4.3k
Philip R. Spradling United States 29 2.3k 1.0× 2.4k 1.2× 475 0.7× 65 0.2× 38 0.3× 103 2.8k
Stéphane Chevaliez France 35 2.9k 1.3× 2.9k 1.4× 831 1.2× 277 1.0× 134 1.0× 144 3.6k
Z Schaff Hungary 9 1.8k 0.8× 1.6k 0.8× 240 0.4× 328 1.2× 201 1.4× 26 2.4k

Countries citing papers authored by Phillip S. Pang

Since Specialization
Citations

This map shows the geographic impact of Phillip S. Pang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip S. Pang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip S. Pang more than expected).

Fields of papers citing papers by Phillip S. Pang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip S. Pang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip S. Pang. The network helps show where Phillip S. Pang may publish in the future.

Co-authorship network of co-authors of Phillip S. Pang

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip S. Pang. A scholar is included among the top collaborators of Phillip S. Pang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip S. Pang. Phillip S. Pang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tan, Susanna K., Maria L. Agostini, Christy M. Hebner, et al.. (2024). A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA). Clinical Infectious Diseases. 79(4). 1054–1061. 7 indexed citations
2.
Telenti, Amalio, Ann M. Arvin, Lawrence Corey, et al.. (2021). After the pandemic: perspectives on the future trajectory of COVID-19. Nature. 596(7873). 495–504. 255 indexed citations breakdown →
3.
Chuang, Wan‐Long, Rong‐Nan Chien, Cheng‐Yuan Peng, et al.. (2016). Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. Journal of Gastroenterology and Hepatology. 31(7). 1323–1329. 22 indexed citations
4.
Sarrazin, Christoph, Hadas Dvory‐Sobol, Evguenia S. Svarovskaia, et al.. (2016). Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology. 151(3). 501–512.e1. 163 indexed citations
5.
Abergel, Armand, Tarik Asselah, Sophie Métivier, et al.. (2016). Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. The Lancet Infectious Diseases. 16(4). 459–464. 65 indexed citations
6.
Cooper, Curtis, Susanna Naggie, Michael S. Saag, et al.. (2016). Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1.. Clinical Infectious Diseases. 63(4). 528–531. 13 indexed citations
7.
Abergel, Armand, V. Loustaud‐Ratti, Sophie Métivier, et al.. (2015). O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. Journal of Hepatology. 62. S219–S220. 26 indexed citations
8.
Gane, Edward, Robert H. Hyland, Di An, et al.. (2015). Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection. Gastroenterology. 149(6). 1454–1461.e1. 139 indexed citations
9.
10.
11.
Kohli, Anita, Rama Kapoor, Zayani Sims, et al.. (2015). Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. The Lancet Infectious Diseases. 15(9). 1049–1054. 117 indexed citations
12.
Cooper, C., Susanna Naggie, M. S. Saag, et al.. (2015). P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study. Journal of Hepatology. 62. S675–S676. 3 indexed citations
13.
Wilson, Eleanor, Sarah Kattakuzhy, Sreetha Sidharthan, et al.. (2015). Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clinical Infectious Diseases. 62(3). 280–288. 38 indexed citations
14.
Osinusi, Anu, Anita Kohli, Amy Nelson, et al.. (2014). Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse. Annals of Internal Medicine. 161(9). 634–638. 58 indexed citations
15.
Guedj, Jérémie, et al.. (2013). 1196 ANALYSIS OF THE KINETICS OF VIRAL DECLINE DURING 14 DAYS OF ADMINISTRATION OF SOFOSBUVIR AND GS-0938. Journal of Hepatology. 58. S486–S487. 1 indexed citations
16.
German, Polina, Phillip S. Pang, Cheng‐Xiong Yang, et al.. (2013). 1195 HEALTHY VOLUNTEER FIRST-IN-HUMAN EVALUATION OF GS-5816, A NOVEL SECOND GENERATION BROAD-GENOTYPIC NS5A INHIBITOR WITH POTENTIAL FOR ONCE-DAILY DOSING. Journal of Hepatology. 58. S486–S486. 9 indexed citations
17.
Pang, Phillip S., et al.. (2011). Structural Map of a MicroRNA-122:Hepatitis C Virus Complex. Journal of Virology. 86(2). 1250–1254. 19 indexed citations
18.
Pang, Phillip S., Paul J. Planet, & Jeffrey S. Glenn. (2009). The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy. PLoS ONE. 4(8). e6579–e6579. 42 indexed citations
19.
Pang, Phillip S., Ahmad Kamal, & Jeffrey S. Glenn. (2009). The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transplantation. 15(9). 1126–1132. 25 indexed citations
20.
Pang, Phillip S., et al.. (2004). Prediction of functional tertiary interactions and intermolecular interfaces from primary sequence data. Journal of Experimental Zoology Part B Molecular and Developmental Evolution. 304B(1). 50–63. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F. Xavier López‐Labrador Breakdown of academic impact, for papers by Nancy P. Lam Breakdown of academic impact, for papers by Khayriyyah Mohd Hanafiah Breakdown of academic impact, for papers by Thelma E. Wiley Breakdown of academic impact, for papers by Enea Spada Breakdown of academic impact, for papers by Mariantonietta Pisaturo Breakdown of academic impact, for papers by Scott Bowden Breakdown of academic impact, for papers by Philip R. Spradling Breakdown of academic impact, for papers by Stéphane Chevaliez Breakdown of academic impact, for papers by Z Schaff
Rankless by CCL
2026